Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:IMDX

Oncocyte Q1 2026 Earnings Report

Oncocyte logo
$3.44 -0.03 (-0.86%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$3.52 +0.08 (+2.18%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Oncocyte EPS Results

Actual EPS
-$0.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncocyte Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncocyte Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oncocyte Earnings Headlines

Oncocyte (NASDAQ:IMDX) Stock Rating Cut to Sell at Wall Street Zen
October 3 at 1:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081354
Contrasting Oncocyte (IMDX) & Its Competitors
October 1 at 6:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073780
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 3 at 1:00 AM  |  Chaikin Analytics (Ad)
Head to Head Analysis: Oncocyte (IMDX) and The Competition
October 1 at 5:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073532
Comparing Precision BioSciences (NASDAQ:DTIL) & Oncocyte (NASDAQ:IMDX)
October 1 at 4:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073318
Analyzing Oncocyte (IMDX) & Its Rivals
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31062994
See More Oncocyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email.

About Oncocyte

Oncocyte (NASDAQ:IMDX)oration is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy. Oncocyte has also pursued tests for evaluating the likelihood that lung nodules are malignant.

Oncocyte was founded in 2009 and has focused primarily on oncology applications in the United States, working with physicians, laboratories, and health care providers. The company has undergone strategic and corporate changes over time, including transactions involving its diagnostic assets. Publicly available information about its current leadership and operations under the NASDAQ symbol IMDX is limited.

View Oncocyte Profile
Earnings Tools